PT-141 10MG
£25.00
- ≥99% purity — HPLC verified
PT-141 is a specialised synthetic melanocortin peptide developed for advanced scientific exploration of melanocortin receptor signalling (MC3R / MC4R) and central neuropeptide pathways, commonly studied in models of motivation, reward, and neuroendocrine signalling.
- Batch tested Purity: ≥ 98% (HPLC, typical)
- CAS Number: 189691-06-3
- Molecular Formula: C50H68N14O10
Guaranteed Safe Checkout
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies are performed outside of the body. These products are not medicines or drugs and have not been approved to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden.
Reconstitution
Use bacteriostatic water. Add solvent slowly along vial wall. Do not shake gently swirl.
Cold Chain
Store lyophilised at 2–8°C. Once reconstituted, keep at 2–8°C and use within 28 days.
Certificate of Analysis
CoA available on request for each batch. HPLC and MS data provided.
- Batch HPLC tested at 98.5%+ purity
- Store frozen long term or in fridge when ready to be used
- Sold for research purposes only
- Contact us for Wholesale Orders
PT-141
Synonyms / Designations: PT-141, Bremelanotide, Melanotan II analogue
CAS Number: 189691-06-3
Molecular Formula: C50H68N14O10
Molecular Weight: ~1025.18 g/mol
Peptide Length: 7 amino acids (cyclic peptide)
Peptide Type: Synthetic melanocortin receptor agonist
Purity: ≥ 99% (HPLC, typical)
Appearance: White to off-white lyophilised powder
Storage: Desiccated, protected from light, stored at –20 °C or below
Solubility: Soluble in water and buffered aqueous solutions
Description & Mechanism
PT-141 is a synthetic cyclic heptapeptide derived from melanocortin peptides and developed for experimental investigation of melanocortin receptor-mediated signalling pathways. It is structurally related to Melanotan II but exhibits distinct receptor selectivity and signalling characteristics.
In biochemical and cellular research systems, PT-141 interacts primarily with melanocortin receptors (MC1R, MC3R, MC4R), initiating intracellular signalling cascades associated with cAMP production and downstream transcriptional regulation. Experimental studies investigate receptor binding affinity, signalling bias, and comparative behaviour relative to other melanocortin analogues. Observed molecular responses depend on concentration, exposure duration, and experimental model.
Applications in Research
- As a molecular probe for studying melanocortin receptor signalling
- Investigation of GPCR-mediated intracellular signalling pathways
- In vitro studies examining receptor selectivity and peptide stability
- Use as a reference compound in neuroendocrine and peptide signalling research
Handling, Reconstitution & Stability
- Weigh under dry conditions; peptide is hygroscopic
- Reconstitute in sterile water or appropriate buffered aqueous solution
- Avoid vigorous agitation during dissolution
- Filter sterilize if required prior to use
- Aliquot and store reconstituted solutions at –20 °C or lower
- Avoid repeated freeze–thaw cycles
Precautions & Notes
- Experimental behaviour is influenced by receptor expression, peptide concentration, and exposure duration
- Buffer composition, pH, and ionic strength may affect peptide stability
- Appropriate controls are recommended to distinguish receptor-specific effects
- Intended strictly for laboratory research use
References
Hadley M.E. et al. Melanocortin peptides and receptors. Endocrine Reviews, 1999.
https://pubmed.ncbi.nlm.nih.gov/10447403/
Wessells H. et al. Melanocortin receptor agonists and signalling mechanisms. Journal of Peptide Research, 2003.
https://pubmed.ncbi.nlm.nih.gov/12622733/
Cone R.D. The melanocortin system and GPCR signalling. Nature Reviews Neuroscience, 2006.
https://pubmed.ncbi.nlm.nih.gov/16755264/
Keywords: PT-141, Bremelanotide, Melanocortin Agonist, Synthetic Peptide, GPCR Signalling
